|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Nonetheless, interrogation of the GIP/GIPR axis on cardiac function in humans will involve the systemic actions of the GIPR within the myocardium and other systems (e.g. adipose tissue, vasculature), which will influence the long-term future of GIPR modification for the treatment of obesity/T2DM.
|
31812593 |
2020 |
|
Cardiovascular Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Although controversy surrounds whether GIPR agonism or antagonism will induce weight loss in obesity/T2DM, such actions undoubtedly will impact cardiovascular function and outcomes since obesity is a major risk factor for cardiovascular disease.
|
31812593 |
2020 |
|
Myocardial Infarction
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Conversely, genetic deletion of GIPR activity within cardiac myocytes of the heart results in robust protection against experimental myocardial infarction.
|
31812593 |
2020 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?
|
31511854 |
2020 |
|
Waist Circumference
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genotype-by-environment interactions inferred from genetic effects on phenotypic variability in the UK Biobank.
|
31453325 |
2019 |
|
Hip circumference
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genotype-by-environment interactions inferred from genetic effects on phenotypic variability in the UK Biobank.
|
31453325 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genotype-by-environment interactions inferred from genetic effects on phenotypic variability in the UK Biobank.
|
31453325 |
2019 |
|
Sodium measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
GWAS for urinary sodium and potassium excretion highlights pathways shared with cardiovascular traits.
|
31409800 |
2019 |
|
Overnutrition
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our results identify GIPR/Rap1 signaling in the brain as a molecular pathway linking overnutrition to the control of neural leptin actions.
|
31403469 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.390 |
Biomarker
|
disease |
BEFREE |
GLP-1R agonists are used clinically to treat T2DM but the use of GIPR agonists remains controversial.
|
31330984 |
2019 |
|
Blood urea nitrogen measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
We highlight GIPR, a potential diabetes drug target, as possibly implicated in the genetic control of urinary potassium excretion, and NRBP1, a locus associated with gout, as plausibly involved in sodium and albumin excretion.
|
30910378 |
2019 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
We highlight GIPR, a potential diabetes drug target, as possibly implicated in the genetic control of urinary potassium excretion, and NRBP1, a locus associated with gout, as plausibly involved in sodium and albumin excretion.
|
30910378 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.390 |
Biomarker
|
disease |
BEFREE |
They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity.
|
30863364 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity.
|
30863364 |
2019 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
They interact with their cognate receptors (GIPR and GLP-1R), which are both members of the class B G protein-coupled receptors (GPCRs), and already recognized as targets for treatment of metabolic diseases, such as type 2 diabetes mellitus (T2DM) and obesity.
|
30863364 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
Exon sequencing of GIPR was performed in 164 children with obesity and insulin resistance and in 80 children with paediatric-onset diabetes of unknown origin.
|
30784161 |
2019 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
Exon sequencing of GIPR was performed in 164 children with obesity and insulin resistance and in 80 children with paediatric-onset diabetes of unknown origin.
|
30784161 |
2019 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
Exon sequencing of GIPR was performed in 164 children with obesity and insulin resistance and in 80 children with paediatric-onset diabetes of unknown origin.
|
30784161 |
2019 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
We suggested that those strongly binding molecules could potentially stimulate GIPR and GLP1R and/or inhibit GCGR which could lead to increased insulin secretion and decreased hepatic glucose production.
|
30650080 |
2019 |
|
Obesity
|
0.200 |
Biomarker
|
disease |
BEFREE |
GIPR-deficient mice showed impaired glucose tolerance with reduced β-cell function and resistance to high-fat diet-induced obesity, whereas GIPR agonists improved glycemia and prevented high-fat diet-induced obesity in mice.
|
30637966 |
2019 |
|
Diabetes
|
0.040 |
Biomarker
|
disease |
BEFREE |
Thus, GLP-1R/GIPR dual agonists can add additional therapeutic efficacy to tailored diabetes care, especially among obese individuals with type 2 diabetes.
|
30637966 |
2019 |
|
Diabetes Mellitus
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, GLP-1R/GIPR dual agonists can add additional therapeutic efficacy to tailored diabetes care, especially among obese individuals with type 2 diabetes.
|
30637966 |
2019 |
|
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
GIPR-deficient mice showed impaired glucose tolerance with reduced β-cell function and resistance to high-fat diet-induced obesity, whereas GIPR agonists improved glycemia and prevented high-fat diet-induced obesity in mice.
|
30637966 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |